Publications by authors named "Nishit B Modi"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

7,220

Total Likes

473

Extended Reach

2,292,496

Social Features

129
R
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Marina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, Ellen K Ritchie, Jason Gotlib, Aaron Gerds, Jeanne Palmer, Kristen Pettit, Uttam K Nath, Abdulraheem Yacoub

N Engl J Med· February 2024

Videos about Article: user user user 1

4 2 125 6 34

View All Article and Social Media Activity
R
Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.
Lee Ping Chew, Yelena Z Ginzburg, Kamini Kirubamoorthy, Sung-Eun Lee, Jae Hoon Lee, Nishit B Modi

Leuk Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants.
Nishit B Modi, Phillip Dinh, Hongqi Xue, Borje Darpo

Clin Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.
Beverly Knight, Brinda Tammara, Nishit B Modi, Shannon Dallas, Saro Mardirosian

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.
Nishit B Modi, Phillip Dinh, Ifode Ajari

Clin Pharmacol Drug Dev· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Nishit B Modi, Sarita Khanna, Sneha Rudraraju, Frank Valone

Drugs R D· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
Nishit B Modi, Richard Shames, Jason D Lickliter, Suneel Gupta

Eur J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.
Anne M Fourie, Xiaoli Cheng, Leon Chang, Carrie Greving, Xinyi Li, Nishit B Modi

Sci Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rusfertide for iron overload in haemochromatosis - Authors' reply.
Kris V Kowdley, Nishit B Modi, Frank H Valone

Lancet Gastroenterol Hepatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kris V Kowdley, Nishit B Modi, Kevork Peltekian, John M Vierling, Christopher Ferris

Lancet Gastroenterol Hepatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.
William J Sandborn, Larry C Mattheakis, Nishit B Modi, David Pugatch, Brian Bressler

Gastroenterology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.
Nishit B Modi, Xiaoli Cheng, Larry Mattheakis, Ching-Chang Hwang, Roya Nawabi

Clin Pharmacol Drug Dev· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
Nishit B Modi, Aravind Mittur, Phillip Dinh, Robert Rubens, Suneel Gupta

Clin Neuropharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
Nishit B Modi, Aravind Mittur, Robert Rubens, Sarita Khanna, Suneel Gupta

Clin Neuropharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.
Robert A Hauser, Aaron Ellenbogen, Sarita Khanna, Suneel Gupta, Nishit B Modi

Neuropsychiatr Dis Treat· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Rytary, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.
Aravind Mittur, Suneel Gupta, Nishit B Modi

Clin Pharmacokinet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation.
Nishit B Modi

AAPS J· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers.
Madhu Sanga, John Banach, Aaron Ledvina, Nishit B Modi, Aravind Mittur

Xenobiotica· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [(14)C]-nefopam in rats.
Jian Yu, Eric Solon, Helen Shen, Nishit B Modi, Aravind Mittur

Xenobiotica· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.
Hsuan-Ming Yao, Ann Hsu, Suneel Gupta, Nishit B Modi

Clin Neuropharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Paul A Nausieda, Ann Hsu, Lawrence Elmer, Ramon A Gil, Joerg Spiegel, Nishit B Modi

J Parkinsons Dis· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
Zhongping Lily Mao, Nishit B Modi

J Clin Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Ann Hsu, Hsuan-Ming Yao, Suneel Gupta, Nishit B Modi

J Clin Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Zhongping Mao, Ann Hsu, Suneel Gupta, Nishit B Modi

J Clin Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Robert A Hauser, Aaron L Ellenbogen, Leo Verhagen Metman, Ann Hsu, Martin J O'Connell, Nishit B Modi

Mov Disord· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis